Product INN: Rimantadini hydrochloridum

Deva: 50 mg tablets

Product ATC Code: J05AC02

Product Description

Remantadin® is used for adults and children over 7 years of age for an early treatment of influenza, as well as for prophylaxis of the disease caused by influenza viruses during epidemic of influenza for adults and children over 7 years of age, and for prophylaxis of tick-borne encephalitis in adults.

Product Mechanism of Action

Rimantadinum is amantadine derivative with a pronounced antiviral activity. It is effective against influenza A virus, as well as has an anti-toxic effect in case of intoxication caused by influenza B virus. Rimantadinum appears to exert its inhibitory effect early in the viral replication cycle, possibly inhibiting the uncoating of the virus. Genetic studies suggest that a virus protein specified by the virion M2 gene plays an important role in the susceptibility of influenza A virus to inhibition by Rimantadinum.
Rimantadinum in vitro prevents virus replication of all antigenic subtypes (H1N1, H2H2 and H3N2) of influenza A virus isolated from humans. Rimantadinum does not appear to interfere with the immunogenicity of inactivated influenza A vaccine.
A quantitative relationship between the in vitro susceptibility of influenza A virus to Rimantadinum and clinical response to therapy has not been established.
Susceptibility test results, expressed as the concentration of the drug required to inhibit virus replication by 50 % or more in a cell culture system, vary greatly (from 4 ng/ml to 20 μg/ml) depending on the assay protocol used, size of the virus inoculum, isolates of the influenza A virus strains tested, and the cell types used.
Rimantadinum-resistant strains of influenza A virus have emerged among freshly isolated epidemic strains in closed settings where Rimantadinum has been used. Resistant viruses have been shown to be transmissible and to cause typical influenza illness. Only 16 (0.8%) cases of Rimantadinum-resistant viruses were registered in the study, where 2017 patients from 43 states were involved during 4 months.
Rimantadinum also inhibits arboviruses that cause tick-borne encephalitis.


Usually Rimantadine 50 mg Tablets is taken orally, after meals, with plenty of liquid. Rimantadine 50 mg Tablets therapy should be initiated as soon as possible, preferably within 48 hours after onset of signs and symptoms of influenza.

Treatment of influenza
For adults: in the first day - 100 mg three times daily, in the second and third day – 100 mg twice a day, in the fourth and fifth day – 100 mg once a day. In the first day of illness 150 mg twice a day or 300 mg at once can be used.
For children: 7-10 years - 50 mg twice a day;
11-14 years - 50 mg three times a day, after 14 y.o. – adult’s doses. Course of treatment is 5 days.

Prophylaxis of influenza
For adults: 50 mg once a day till 30 days.
For children from 7 y.o. - 50 mg once a day during 15 days.

Prophylaxis of tick-born encephalitis after tick’s bite
For adults: 100 mg twice a day during 3 days, in several cases (according to physician’s indication) – 5 days.
Prophylaxis should be started immediately after tick’s bite, but not later than within 48 hours.

Prophylaxis of tick-born encephalitis without tick’s bite
In separate cases (for risk groups, for hiking tours participants in wooded and overgrown countryside, for persons living in tents etc.) adults can use 50 mg twice a day up to 15 days for prophylaxis.


Before use, carefully read the instructions. Consult your doctor or pharmacist about the use of medicines.
Medicines unreasonable use is harmful to health.